ArticlePharmacoEconomics2022

Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.

Woojung Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.